Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Secondary Efficacy Outcomes from Two Pivotal Phase 3 Trials

Main Article Content

Linda Stein Gold
Henry Ford Health System, Detroit, MI, USA

Andrew Blauvelt
Oregon Medical Research Center, Portland, OR, USA

April Armstrong
University of Southern California

Seemal Desai
Innovative Dermatology

Howard Sofen
UCLA

Lawrence Green
George Washington University School of Medicine

Steve Tyring
University of Texas Health Science Center, Houston, TX

Laura Ferris
UPMC

Philip Brown
Dermavant Sciences, Inc., Morrisville, NC, USA

David Rubenstein
Dermavant Sciences, Inc., Morrisville, NC, USA

Stephen Piscitelli
Dermavant Sciences, Inc., Morrisville, NC, USA

Anna Tallman
Dermavant Sciences, Inc., Morrisville, NC, USA

Leon Kircik
Mount Sinai

Keywords

psoriasis

Abstract

N/A

References

1. Menter A, et al. J Am Acad Dermatol. 2008;58:826–850;

2. Lebwohl M, et al. N Engl J Med. 2021;385:2219–2229;

3. Robbins K, et al. J Am Acad Dermatol. 2019;80:714–721;

4. Stein Gold L, et al. J Am Acad Dermatol. 2021;84:624–631; 5. Strober B, et al. Innovations in Dermatology Virtual Spring
Conference 2021, Poster Presentation, March 16–20, 2021

Article Sidebar

Poster PDF
Published
Mar 4, 2022
DOI https://doi.org/10.25251/skin.6.supp.6

Article Details

How to Cite
[1]
Stein Gold, L., Blauvelt, A. , Armstrong , A., Desai, S., Sofen, H., Green, L., Tyring, S., Ferris, L., Brown, P. , Rubenstein, D., Piscitelli, S., Tallman, A. and Kircik, L. 2022. Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Secondary Efficacy Outcomes from Two Pivotal Phase 3 Trials. SKIN The Journal of Cutaneous Medicine. 6, 2 (Mar. 2022), s6. DOI:https://doi.org/10.25251/skin.6.supp.6.
Issue
Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Section
Poster Presenations From Winter Clinical 2022 and FC PANP 2021: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>